Global transcriptional response of oral squamous cell carcinoma cell lines to health-associated oral bacteria - an in vitro study

References

• Ram H, Sarkar J, Kumar H, et al. Oral cancer: risk factors and molecular pathogenesis. J Maxillofac Oral Surg. 2011;10(2):132–10.
   PubMedGoogle Scholar
• Al-Hebshi NN, Borgnakke WS, Johnson NW. The microbiome of oral squamous cell carcinomas: a functional perspective. Curr Oral Health Rep. 2019;6(2):145–160.
   Google Scholar
• Perera M, Al-Hebshi NN, Speicher DJ, et al. Emerging role of bacteria in oral carcinogenesis: a review with special reference to perio-pathogenic bacteria. J Oral Microbiol. 2016;8:32762.
   PubMed Web of Science ®Google Scholar
• Yost S, Stashenko P, Choi Y, et al. Increased virulence of the oral microbiome in oral squamous cell carcinoma revealed by metatranscriptome analyses. Int J Oral Sci. 2018;10(4):32.
   PubMedGoogle Scholar
• Zhang Z, Yang J, Feng Q, et al. Compositional and functional analysis of the microbiome in tissue and saliva of oral squamous cell carcinoma. Front Microbiol. 2019;10:1439.
   PubMed Web of Science ®Google Scholar
• Al-Hebshi NN, Nasher AT, Maryoud MY, et al. Inflammatory bacteriome featuring Fusobacterium nucleatum and Pseudomonas aeruginosa identified in association with oral squamous cell carcinoma. Sci Rep. 2017;7(1):1834.
   PubMed Web of Science ®Google Scholar
• Guerrero-Preston R, White JR, Godoy-Vitorino F, et al. High-resolution microbiome profiling uncovers Fusobacterium nucleatum, Lactobacillus gasseri/johnsonii, and Lactobacillus vaginalis associated to oral and oropharyngeal cancer in saliva from HPV positive and HPV negative patients treated with surgery and chemo-radiation. Oncotarget. 2017;8(67):110931–110948.
   PubMedGoogle Scholar
• Yang CY, Yeh YM, Yu HY, et al. Oral microbiota community dynamics associated with oral squamous cell carcinoma staging. Front Microbiol. 2018;9:862.
   PubMed Web of Science ®Google Scholar
• Fong W, Li Q, Yu J. Gut microbiota modulation: a novel strategy for prevention and treatment of colorectal cancer. Oncogene. 2020;39(26):4925–4943.
   PubMed Web of Science ®Google Scholar
• Duong MT, Qin Y, You SH, et al. Bacteria-cancer interactions: bacteria-based cancer therapy. Exp Mol Med. 2019;51(12):1–15.
   PubMedGoogle Scholar
• Panebianco C, Andriulli A, Pazienza V. Pharmacomicro- biomics: exploiting the drug-microbiota interactions in anticancer therapies. Microbiome. 2018;6(1):92.
   PubMedGoogle Scholar
• Ohshima J, Wang Q, Fitzsimonds ZR, et al. Streptococcus gordonii programs epithelial cells to resist ZEB2 induction by Porphyromonas gingivalis. Proc Natl Acad Sci U S A. 2019;116(17):8544–8553.
   Web of Science ®Google Scholar
• Baraniya D, Jain V, Lucarelli R, et al. Screening of health-associated oral bacteria for anticancer properties in vitro. Front Cell Infect Microbiol. 2020;10:575656.
   PubMed Web of Science ®Google Scholar
• Amer A, Galvin S, Healy CM, et al. The microbiome of potentially malignant oral leukoplakia exhibits enrichment for fusobacterium, leptotrichia, campylobacter, and rothia species. Front Microbiol. 2017;8:2391.
   Web of Science ®Google Scholar
• Pushalkar S, Ji X, Li Y, et al. Comparison of oral microbiota in tumor and non-tumor tissues of patients with oral squamous cell carcinoma. BMC Microbiol. 2012;12:144.
   PubMed Web of Science ®Google Scholar
• Schmidt BL, Kuczynski J, Bhattacharya A, et al. Changes in abundance of oral microbiota associated with oral cancer. PLoS One. 2014;9(6):e98741.
   PubMed Web of Science ®Google Scholar
• Hayes RB, Ahn J, Fan X, et al. Association of oral microbiome with risk for incident head and neck squamous cell cancer. JAMA Oncol. 2018;4(3):358–365.
   PubMed Web of Science ®Google Scholar
• Zhao H, Chu M, Huang Z, et al. Variations in oral microbiota associated with oral cancer. Sci Rep. 2017;7(1):11773.
   PubMed Web of Science ®Google Scholar
• Perera M, Al-Hebshi NN, Perera I, et al. Inflammatory bacteriome and oral squamous cell carcinoma. J Dent Res. 2018;97(6):725–732.
   PubMed Web of Science ®Google Scholar
• Wang J, Li Y. CD36 tango in cancer: signaling pathways and functions. Theranostics. 2019;9(17):4893–4908.
   PubMed Web of Science ®Google Scholar
• Kumari N, Dwarakanath BS, Das A, et al. Role of interleukin-6 in cancer progression and therapeutic resistance. Tumour Biol. 2016;37(9):11553–11572.
   PubMedGoogle Scholar
• Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer. 2009;9(5):361–371.
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Mountcastle SE, Cox SC, Sammons RL, et al. A review of co-culture models to study the oral microenvironment and disease. J Oral Microbiol. 2020;12(1):1773122.
   Web of Science ®Google Scholar
• Rodrigues J, Heinrich MA, Teixeira LM, et al. 3D in vitro model (R)evolution: unveiling tumor-stroma interactions. Trends Cancer. 2021;7(3):249–264.
   PubMed Web of Science ®Google Scholar
• Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer. 2017;17(2):93–115.
   PubMed Web of Science ®Google Scholar
• DiPaola RS. To arrest or not to G(2)-M Cell-cycle arrest: commentary re: a. K. Tyagi et al., Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G(2)-M arrest, and apoptosis. Clin Cancer Res. 2002;8:3512–3519. Clin Cancer Res. 2002;8(11):3311-4.
   PubMed Web of Science ®Google Scholar
• Prevo R, Pirovano G, Puliyadi R, et al. CDK1 inhibition sensitizes normal cells to DNA damage in a cell cycle dependent manner. Cell Cycle. 2018;17(12):1513–1523.
   PubMed Web of Science ®Google Scholar
• Han T, Goralski M, Capota E, et al. The antitumor toxin CD437 is a direct inhibitor of DNA polymerase alpha. Nat Chem Biol. 2016;12(7):511–515.
   Web of Science ®Google Scholar
• An X, Xu F, Luo R, et al. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer. BMC Cancer. 2018;18(1):331.
   PubMedGoogle Scholar
• Wang XK, Wang QQ, Huang JL, et al. Novel candidate biomarkers of origin recognition complex 1, 5 and 6 for survival surveillance in patients with hepatocellular carcinoma. J Cancer. 2020;11(7):1869–1882.
   Web of Science ®Google Scholar
• Gupta R, Dong Y, Solomon PD, et al. Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A. Proc Natl Acad Sci U S A. 2014;111(30):E3062–71.
   Web of Science ®Google Scholar
• Gulappa T, Reddy RS, Suman S, et al. Molecular interplay between cdk4 and p21 dictates G0/G1 cell cycle arrest in prostate cancer cells. Cancer Lett. 2013;337(2):177–183.
   Web of Science ®Google Scholar
• Liu YW, Xia R, Lu K, et al. LincRNAFEZF1-AS1 represses p21 expression to promote gastric cancer proliferation through LSD1-Mediated H3K4me2 demethylation. Mol Cancer. 2017;16(1):39.
   Google Scholar
• de Carcer G. The mitotic cancer target polo-like kinase 1: oncogene or tumor suppressor? Genes (Basel). 2019;10(3):208.
   PubMed Web of Science ®Google Scholar
• Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140(6):883–899.
   PubMed Web of Science ®Google Scholar
• Muller-Hubenthal B, Azemar M, Lorenzen D, et al. Tumour biology: tumour-associated inflammation versus antitumor immunity. Anticancer Res. 2009;29(11):4795–4805.
   Web of Science ®Google Scholar
• Rosano L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2013;13(9):637–651.
   Web of Science ®Google Scholar
• Wang S, Zhang Y. HMGB1 in inflammation and cancer. J Hematol Oncol. 2020;13(1):116.
   PubMed Web of Science ®Google Scholar
• Brooks AJ, Putoczki T. JAK-STAT signalling pathway in cancer. Cancers (Basel). 2020;12(7):1971.
   Web of Science ®Google Scholar
• Quintero-Fabian S, Arreola R, Becerril-Villanueva E, et al. Role of matrix metalloproteinases in angiogenesis and cancer. Front Oncol. 2019;9:1370.
   PubMed Web of Science ®Google Scholar
• Hajjari M, Salavaty A. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med. 2015;12(1):1–9.
   PubMed Web of Science ®Google Scholar
• Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2(2):132–141.
   PubMedGoogle Scholar
• Fisher DT, Appenheimer MM, Evans SS. The two faces of IL-6 in the tumor microenvironment. Semin Immunol. 2014;26(1):38–47.
   PubMed Web of Science ®Google Scholar
• Li T, Wu B, Yang T, et al. The outstanding antitumor capacity of CD4(+) T helper lymphocytes. Biochim Biophys Acta Rev Cancer. 2020;1874(2):188439.
   Web of Science ®Google Scholar
• Dhiman VK, Bolt MJ, White KP. Nuclear receptors in cancer - uncovering new and evolving roles through genomic analysis. Nat Rev Genet. 2018;19(3):160–174.
   PubMed Web of Science ®Google Scholar
• Huang W, Glass CK. Nuclear receptors and inflammation control: molecular mechanisms and pathophysiological relevance. Arterioscler Thromb Vasc Biol. 2010;30(8):1542–1549.
   Web of Science ®Google Scholar
• Campbell MJ, Trump DL. Vitamin D receptor signaling and cancer. Endocrinol Metab Clin North Am. 2017;46(4):1009–1038.
   Web of Science ®Google Scholar
• Heublein S, Mayr D, Meindl A, et al. Vitamin D receptor, retinoid X receptor and peroxisome proliferator-activated receptor gamma are overexpressed in BRCA1 mutated breast cancer and predict prognosis. J Exp Clin Cancer Res. 2017;36(1):57.
   Google Scholar
• Rojo de la Vega M, Chapman E, Zhang DD. NRF2 and the hallmarks of cancer. Cancer Cell. 2018;34(1):21–43.
   PubMed Web of Science ®Google Scholar
• Xu W, Liu LZ, Loizidou M, et al. The role of nitric oxide in cancer. Cell Res. 2002;12(5–6):311–320.
   PubMed Web of Science ®Google Scholar
• Leone A, Nigro C, Nicolo A, et al. The dual-role of methylglyoxal in tumor progression - novel therapeutic approaches. Front Oncol. 2021;11:645686.
   Web of Science ®Google Scholar
• Park JB, Lee CS, Jang JH, et al. Phospholipase signalling networks in cancer. Nat Rev Cancer. 2012;12(11):782–792.
   PubMed Web of Science ®Google Scholar
• Hoxhaj G, Manning BD. The PI3K-AKT network at the interface of oncogenic signalling and cancer metabolism. Nat Rev Cancer. 2020;20(2):74–88.
   PubMed Web of Science ®Google Scholar
• Wu JS, Zheng M, Zhang M, et al. Porphyromonas gingivalis promotes 4-nitroquinoline-1-oxide-induced oral carcinogenesis with an alteration of fatty acid metabolism. Front Microbiol. 2018;9:2081.
   PubMed Web of Science ®Google Scholar
• Yilmaz O, Jungas T, Verbeke P, et al. Activation of the phosphatidylinositol 3-kinase/Akt pathway contributes to survival of primary epithelial cells infected with the periodontal pathogen Porphyromonas gingivalis. Infect Immun. 2004;72(7):3743–3751.
   PubMed Web of Science ®Google Scholar